Skip to main content

Advertisement

SpringerLink
Log in

The unrelenting fall of the pharmacological treatment of obesity

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Nowadays pharmacological therapy to limit obesity has reached a critical stage: not only have Authorities limited the use of antiobesity drugs due to their proven inefficacy and dangerous side effects, but bariatric surgery has delivered better results. At present, when the number of obese subjects is growing exponentially worldwide and more and more pathological mechanisms inducing fat accumulation have been discovered, no drugs are available to help patients and physicians to limit one the most dreadful causes of death. Following the failures of promising drugs as sibutramine and rimonabant, many companies stopped to invest in the field of obesity pharmacotherapy. At the same time, leading Authorities have started to require more solid evidence before providing authorization for these drugs to enter the market. This review aims at revising the failed promises of antiobesity drugs and describing the few potential future candidates in order to shed some light in the still uncertain field of antiobesity drugs. It also provides a critical contribution to the ongoing debate among scientists, clinicians, patients and Authorities on the possibility to treat obesity with pharmacological drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. WHO Library Cataloguing-in-Publication Data, Surveillance of chronic disease: risk factors: country-level data and comparable estimates (SuRF reports; 2), https://apps.who.int/infobase/Publicfiles/SuRF2.pdf

  2. C.L. Ogden, M.D. Carroll, B.K. Kit, K.M. Flegal, Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief 82, 1–8 (2012)

    PubMed  Google Scholar 

  3. European Commission, Eurostat, Overweight and obesity—BMI statistics (2011), http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Overweight_and_obesity_-_BMI_statistics

  4. International Association for the Study of Obesity (IASO), http://www.iaso.org/

  5. E.S. Leblanc, E. O’Connor, E.P. Whitlock, C.D. Patnode, T. Kapka, Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 155, 434–447 (2011)

    Article  PubMed  Google Scholar 

  6. R. Estruch, E. Ros, J. Salas-Salvadó, M.I. Covas, D. Pharm, D. Corella, F. Arós, E. Gómez-Gracia, V. Ruiz-Gutiérrez, M. Fiol, J. Lapetra, R.M. Lamuela-Raventos, L. Serra-Majem, X. Pintó, J. Basora, M.A. Muñoz, J.V. Sorlí, J.A. Martínez, M.A. Martínez-González, The PREDIMED Study Investigators, Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279–1290 (2013)

    Article  PubMed  CAS  Google Scholar 

  7. J.L. Colquitt, J. Picot, E. Loveman, A.J. Clegg, Surgery for obesity. Cochrane Database Syst. Rev. 15, CD003641 (2009)

    Google Scholar 

  8. L. Sjöström, A.K. Lindroos, M. Peltonen, J. Torgerson, C. Bouchard, B. Carlsson, S. Dahlgren, B. Larsson, K. Narbro, C.D. Sjöström, M. Sullivan, H. Wedel, Swedish Obese Subjects Study Scientific Group, Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683–2693 (2004)

    Article  PubMed  Google Scholar 

  9. L. Sjöström, Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J. Intern. Med. 273, 219–234 (2013)

    Article  PubMed  Google Scholar 

  10. L. Sjöström, A. Gummesson, C.D. Sjöström, K. Narbro, M. Peltonen, H. Wedel, C. Bengtsson, C. Bouchard, B. Carlsson, S. Dahlgren, P. Jacobson, K. Karason, J. Karlsson, B. Larsson, A.K. Lindroos, H. Lönroth, I. Näslund, T. Olbers, K. Stenlöf, J. Torgerson, L.M. Carlsson, Swedish Obese Subjects Study, Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 10, 653–662 (2009)

    Article  PubMed  Google Scholar 

  11. L. Sjöström, K. Narbro, C.D. Sjöström, K. Karason, B. Larsson, H. Wedel, T. Lystig, M. Sullivan, C. Bouchard, B. Carlsson, C. Bengtsson, S. Dahlgren, A. Gummesson, P. Jacobson, J. Karlsson, A.K. Lindroos, H. Lönroth, I. Näslund, T. Olbers, K. Stenlöf, J. Torgerson, G. Agren, L.M. Carlsson, Swedish Obese Subjects Study, Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357, 741–752 (2007)

    Article  PubMed  Google Scholar 

  12. C. Gazzaruso, S. Giordanetti, A. La Manna, M. Celsa, E. De Amici, C. Turpini, A. Catona, P. Fratino, Weight loss after Swedish Adjustable Gastric Banding: relationships to insulin resistance and metabolic syndrome. Obes. Surg. 12, 841–845 (2002)

    Article  PubMed  Google Scholar 

  13. A.P. Shukla, S.M. Ahn, R.T. Patel, M.W. Rosenbaum, F. Rubino, Surgical treatment of type 2 diabetes: the surgeon perspective. Endocrine 40, 151–161 (2011)

    Article  PubMed  CAS  Google Scholar 

  14. B. Laferrère, Do we really know why diabetes remits after gastric bypass surgery? Endocrine 40, 162–167 (2011)

    Article  PubMed  Google Scholar 

  15. K. Sjöholm, A. Anveden, M. Peltonen, P. Jacobson, S. Romeo, P.A. Svensson, L. Sjöström, L.M. Carlsson, Evaluation of Current Eligibility Criteria for Bariatric Surgery: diabetes prevention and risk factor changes in the Swedish Obese Subjects (SOS) study. Diabetes Care 36(5), 1335–1340 (2013)

    Article  PubMed  Google Scholar 

  16. M. Fried, V. Hainer, A. Basdevant, H. Buchwald, M. Deitel, N. Finer, J.W. Greve, F. Horber, E. Mathus-Vliegen, N. Scopinaro, R. Steffen, C. Tsigos, R. Weiner, K. Widhalm, Interdisciplinary European guidelines on surgery of severe obesity. Obes. Facts 1, 52–59 (2008)

    Article  PubMed  Google Scholar 

  17. J.B. Dixon, P. Zimmet, K.G. Alberti, F. Rubino, Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet. Med. 28, 628–642 (2011)

    Article  PubMed  CAS  Google Scholar 

  18. G. Bray, The battle of the bulge: a history of obesity research (Dorrance Publishing Co., Pittsburg, 2007)

    Google Scholar 

  19. R.B. McFee, T.R. Caraccio, M.A. McGuigan, S.A. Reynolds, P. Bellanger, Dying to be thin: a dinitrophenol related fatality. Vet. Hum. Toxicol. 46, 251–254 (2004)

    PubMed  CAS  Google Scholar 

  20. L. Phillips, M.A. Singer, Peripheral neuropathy due to dinitrophenol used for weight loss: something old, something new. Neurology 80, 773–774 (2013)

    Article  PubMed  Google Scholar 

  21. G. Glazer, Long-term pharmacotherapy of obesity 2000: a re-view of efficacy and safety. Arch. Intern. Med. 161, 1814–1824 (2001)

    Article  PubMed  CAS  Google Scholar 

  22. Z. Li, M. Maglione, W. Tu, W. Mojica, D. Arterburn, L.R. Shugarman, L. Hilton, M. Suttorp, V. Solomon, P.G. Shekelle, S.C. Morton, Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. 142, 532–546 (2005)

    Article  PubMed  CAS  Google Scholar 

  23. J.G. Kang, C.Y. Park, J.H. Kang, Y.W. Park, S.W. Park, Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes. Metab. 12, 876–882 (2010)

    Article  PubMed  CAS  Google Scholar 

  24. C.K. Haddock, W.S. Poston, P.L. Dill, J.P. Foreyt, M. Ericsson, Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26, 262–273 (2002)

    Article  PubMed  CAS  Google Scholar 

  25. C. Cercato, V.A. Roizenblatt, C.C. Leanca, A. Segal, A.P. Lopes Filho, M.C. Mancini, A. Halpern, A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int. J. Obes. (Lond.) 33, 857–865 (2009)

    Article  CAS  Google Scholar 

  26. F. Brenot, P. Herve, P. Petitpretz, F. Parent, P. Duroux, G. Simonneau, Primary pulmonary hypertension and fenfluramine use. Br. Heart J. 70, 537–541 (1993)

    Article  PubMed  CAS  Google Scholar 

  27. J. McMurray, P. Bloomfield, H.C. Miller, Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ 292, 239–240 (1986)

    Article  PubMed  CAS  Google Scholar 

  28. J.G. Kang, C.Y. Park, Anti-obesity drugs: a review about their effects and safety. Diabetes Metab. J. 36, 13–25 (2012)

    Article  PubMed  Google Scholar 

  29. H.M. Connolly, J.L. Crary, M.D. McGoon, D.D. Hensrud, B.S. Edwards, W.D. Edwards, H.V. Schaff, Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. 337, 581–588 (1997)

    Article  PubMed  CAS  Google Scholar 

  30. D. Rucker, R. Padwal, S.K. Li, C. Curioni, D.C. Lau, Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335, 1194–1199 (2007)

    Article  PubMed  CAS  Google Scholar 

  31. O. Bosello, M.O. Carruba, E. Ferrannini, C.M. Rotella, Sibutra-mine lost and found. Eat. Weight Disord. 7, 161–167 (2002)

    Article  PubMed  CAS  Google Scholar 

  32. European Medicine Agency (EMA), Opinion following an Article 31 referral for Sibutramine International Non-Proprietary Name (INN): Sibutramine: Background information and Annexes I, II, III. EMA website, http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_31/WC500013923.pdf

  33. W.P.T. James, I.D. Caterson, W. Coutinho, N. Finer, L.F. Van Gaal, A.P. Maggioni, C. Torp-Pedersen, A.M. Sharma, G.M. Shepherd, R.A. Rode, C.L. Renz, SCOUT Investigators, Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363, 905–917 (2010)

    Article  PubMed  CAS  Google Scholar 

  34. European Medicine Agency (EMA), Questions and answers on the suspension of medicines containing sibutramine. EMA website, http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_107/WC500094238.pdf

  35. US Department of Health and Human Services, Food and Drug Administration (FDA), FDA Drug Safety Communication: FDA recommends against the continued use of meridia (sibutramine). FDA website, http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm

  36. C. Quarta, R. Mazza, S. Obici, R. Pasquali, U. Pagotto, Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol. Med. 17, 518–526 (2011)

    Article  PubMed  CAS  Google Scholar 

  37. G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali, G.L. Gessa, Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63, 113–117 (1998)

    Article  Google Scholar 

  38. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, S. Rössner, RIO-Europe Study Group, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389–1397 (2005)

    Article  PubMed  Google Scholar 

  39. F.X. Pi-Sunyer, L.J. Aronne, H.M. Heshmati, J. Devin, J. Rosenstock, RIO-North America Study Group, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761–775 (2006)

    Article  PubMed  CAS  Google Scholar 

  40. L.F. Van Gaal, A.J. Scheen, A.M. Rissanen, S. Rössner, C. Hanotin, O. Ziegler, RIO-Europe Study Group, Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J. 29, 1761–1771 (2008)

    Article  PubMed  Google Scholar 

  41. A.J. Scheen, N. Finer, P. Hollander, M.D. Jensen, L.F. Van Gaal, RIO-Diabetes Study Group, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368, 1660–1672 (2006)

    Article  PubMed  CAS  Google Scholar 

  42. J. Rosenstock, P. Hollander, S. Chevalier, A. Iranmanesh, SERENADE Study Group, SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31, 2169–2176 (2008)

    Article  PubMed  Google Scholar 

  43. J.P. Després, A. Golay, L. Sjöström, Rimonabant in Obesity-Lipids Study Group, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121–2134 (2005)

    Article  PubMed  Google Scholar 

  44. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, A. Astrup, Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706–1713 (2007)

    Article  PubMed  CAS  Google Scholar 

  45. European Medicine Agency (EMA), Public statement on Acomplia (rimonabant). EMA website, http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf

  46. E.J. Topol, M.G. Bousser, K.A. Fox, M.A. Creager, J.P. Despres, J.D. Easton, C.W. Hamm, G. Montalescot, P.G. Steg, T.A. Pearson, E. Cohen, C. Gaudin, B. Job, J.H. Murphy, D.L. Bhatt, CRESCENDO Investigators, Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376, 517–523 (2010)

    Article  PubMed  CAS  Google Scholar 

  47. J.E. Boesten, J. Kaper, H.E. Stoffers, A.A. Kroon, O.C. van Schayck, Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE). Fam. Pract. 29, 521–527 (2012)

    Article  PubMed  Google Scholar 

  48. B. Borgstrom, Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta 962, 308–316 (1988)

    Article  PubMed  CAS  Google Scholar 

  49. S. Rossner, L. Sjostrom, R. Noack, A.E. Meinders, G. Noseda, European Orlistat Obesity Study Group, Weight loss, weight maintenance, and improved cardiovascu-lar risk factors after 2 years treatment with orlistat for obesity. Obes. Res. 8, 49–61 (2000)

    Article  PubMed  CAS  Google Scholar 

  50. J.S. Torgerson, J. Hauptman, M.N. Boldrin, L. Sjostrom, XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155–161 (2004)

    Article  PubMed  CAS  Google Scholar 

  51. US Department of Health and Human Services, Food and Drug Administration (FDA), Questions and answers: orlistat and severe liver injury. FDA drug bulletin, 26 May 2010. FDA website, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm213040.htm

  52. M.A. Weir, M.M. Beyea, T. Gomes, D.N. Juurlink, M. Mamdani, P.G. Blake, R. Wald, A.X. Garg, Orlistat and acute kidney injury: an analysis of 953 patients. Arch. Intern. Med. 171, 703–704 (2011)

    Article  PubMed  Google Scholar 

  53. K.M. Gadde, D.B. Allison, D.H. Ryan, C.A. Peterson, B. Troupin, M.L. Schwiers, W.W. Day, Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341–1352 (2011)

    Article  PubMed  CAS  Google Scholar 

  54. M.H. Davidson, S. Tonstad, S. Oparil, M. Schwiers, W.W. Day, C.H. Bowden, Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). Am. J. Cardiol. (2013). doi:10.1016/j.amjcard.2012.12.038

    Google Scholar 

  55. European Medicine Agency (EMA), Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine/topiramate). EMA website, http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500134085.pdf

  56. US Department of Health and Human Services, Food and Drug Administration (FDA). FDA website, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s001lbl.pdf

  57. US Department of Health and Human Services, Food and Drug Administration (FDA), Guidance for industry. Developing products for weight management. FDA website, http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071612.pdf

  58. European Medicine Agency (EMA), Committee for Medicinal Products for Human use (CHMP), Guideline on clinical investigation of medicinal products used in weight control. EMA website, http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003213.pdf

  59. A.B. Goldfine, Assessing the cardiovascular safety of diabetes therapies. N. Engl. J. Med. 359, 1092–1095 (2008)

    Article  PubMed  CAS  Google Scholar 

  60. US Department of Health and Human Services, Food and Drug Administration (FDA), Briefing information for the March 28–29, 2012 Meeting of the Endocrinological and Metabolic Drug Advisory Committee. FDA website, http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm297239.htm

  61. D.D. Lam, M.J. Przydzial, S.H. Ridley, G.S. Yeo, J.J. Rochford, S. O’Rahilly, L.K. Heisler, Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 149, 1323–1328 (2008)

    Article  PubMed  CAS  Google Scholar 

  62. Y. Xu, J.E. Jones, D. Kohno, K.W. Williams, C.E. Lee, M.J. Choi, J.G. Anderson, L.K. Heisler, J.M. Zigman, B.B. Lowell, J.K. Elmquist, 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60, 582–589 (2008)

    Article  PubMed  CAS  Google Scholar 

  63. US Department of Health and Human Services, Food and Drug Administration (FDA), FDA approves Belviq to treat some overweight or obese adults. FDA website, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm?utm_source=twitterfeed%26utm_medium=twitter

  64. S.R. Smith, N.J. Weissman, C.M. Anderson, M. Sanchez, E. Chuang, S. Stubbe, H. Bays, W.R. Shanahan, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group, Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245–256 (2010)

    Article  PubMed  CAS  Google Scholar 

  65. M.C. Fidler, M. Sanchez, B. Raether, N.J. Weissman, S.R. Smith, W.R. Shanahan, C.M. Anderson, BLOSSOM Clinical Trial Group, A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96, 3067–3077 (2011)

    Article  PubMed  CAS  Google Scholar 

  66. P.M. O’Neil, S.R. Smith, N.J. Weissman, M.C. Fidler, M. Sanchez, J. Zhang, B. Raether, C.M. Anderson, W.R. Shanahan, Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 20, 1426–1436 (2012)

    Article  Google Scholar 

  67. E.W. Chan, Y. He, C.S. Chui, A.Y. Wong, W.C. Lau, I.C. Wong, Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes. Rev. (2013). doi:10.1111/obr.12015

    PubMed  Google Scholar 

  68. European Medicine Agency (EMA), Pharmacovigilance Risk Assessment Committee (PRAC). Draft agenda of meeting 7–10 Jan 2013. EMA website, http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2013/01/WC500137109.pdf

  69. S. Madsbad, Treatment of type 2 diabetes with incretin-based therapies. Lancet 373, 438–439 (2009)

    Article  PubMed  Google Scholar 

  70. A. Astrup, R. Carraro, N. Finer, A. Harper, M. Kunesova, M.E. Lean, L. Niskanen, M.F. Rasmussen, A. Rissanen, S. Rössner, M.J. Savolainen, L. Van Gaal, Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. (Lond.) (2013). doi:10.1038/ijo.2012.19236

    Google Scholar 

  71. A. Astrup, S. Rössner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, J. Madsen, M.F. Rasmussen, M.E. Lean, NN8022-1807 Study Group, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606–1616 (2009)

    Article  PubMed  CAS  Google Scholar 

  72. J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, C.R. Heilmann, B.J. Hoogwerf, A. Gao, M.K. Boardman, M. Fineman, L. Porter, G. Schernthaner, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381, 117–124 (2013)

    Article  PubMed  CAS  Google Scholar 

  73. S.S. Torekov, S. Madsbad, J.J. Holst, Obesity—an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes. Rev. 12, 593–601 (2011)

    Article  PubMed  CAS  Google Scholar 

  74. K.M. Gadde, D.M. Franciscy, H.R. Wagner 2nd, K.R. Krishnan, Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289, 1820–1825 (2003)

    Article  PubMed  CAS  Google Scholar 

  75. N.T. Bello, M.R. Zahner, Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr. Opin. Investig. Drugs 10, 1105–1116 (2009)

    PubMed  CAS  Google Scholar 

  76. A. Sjödin, C. Gasteyger, A.L. Nielsen, A. Raben, J.D. Mikkelsen, J.K. Jensen, D. Meier, A. Astrup, The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int. J. Obes. (Lond.) 34, 1634–1643 (2010)

    Article  Google Scholar 

  77. A. Astrup, S. Madsbad, L. Breum, T.J. Jensen, J.P. Kroustrup, T.M. Larsen, Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372, 1906–1913 (2008)

    Article  PubMed  CAS  Google Scholar 

  78. S.A. Doggrell, Tesofensine—a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Expert Opin. Investig. Drugs 18, 1043–1046 (2009)

    Article  PubMed  CAS  Google Scholar 

  79. R.A.H. Adan, L.J.M.J. Vandershuren, S.E. la Fleur, Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol. Sci. 29, 208–217 (2008)

    Article  PubMed  CAS  Google Scholar 

  80. F.L. Greenway, M.J. Whitehouse, M. Guttadauria, J.W. Anderson, R.L. Atkinson, K. Fujioka, K.M. Gadde, A.K. Gupta, P. O’Neil, D. Schumacher, D. Smith, E. Dunayevich, G.D. Tollefson, E. Weber, M.A. Cowley, Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17, 30–39 (2009)

    Article  CAS  Google Scholar 

  81. F.L. Greenway, K. Fujioka, R.A. Plodkowski, S. Mudaliar, M. Guttadauria, J. Erickson, D.D. Kim, E. Dunayevich, COR-I Study Group, Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376, 595–605 (2010)

    Article  PubMed  CAS  Google Scholar 

  82. T.A. Wadden, J.P. Foreyt, G.D. Foster, J.O. Hill, S. Klein, P.M. O’Neil, M.G. Perri, F.X. Pi-Sunyer, C.L. Rock, J.S. Erickson, H.N. Maier, D.D. Kim, E. Dunayevich, Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 19, 110–120 (2011)

    Article  CAS  Google Scholar 

  83. C. Apovian, L. Aronne, D. Rubino, C. Still, H. Wyatt, C. Burns, D. Kim, E. Dunayevich, COR-II Study Group, A randomized, phase 3 Trial of naltrexone SR/Bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) (2013). doi:10.1002/oby.20309

    Google Scholar 

  84. US National Institute of Health (NIH), http://clinicaltrials.gov/ct2/show/record/NCT00474630?term=contrave&rank=4

  85. Orexigen® Press Release, http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle_pf&id=1441827

  86. US Department of Health and Human Services, Food and Drug Administration (FDA), FDA briefing document. FDA website, http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm235671.pdf

  87. US National Institute of Health (NIH), http://clinicaltrials.gov/ct2/show/NCT01601704?term=contrave&rank=3

  88. K.M. Gadde, G.M. Yonish, M.S. Foust, H.R. Wagner, Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J. Clin. Psychiatry 68, 1226–1229 (2007)

    Article  PubMed  CAS  Google Scholar 

  89. L.L. Ioannides-Demos, L. Piccenna, J.J. McNeil, Pharmacotherapies for obesity: past, current, and future therapies. J. Obes. (2011). doi:10.1155/2011/179674

    PubMed  Google Scholar 

  90. Orexigen® Press Release. San Diego, 9 May 2012, http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle_print&ID=1694059&highlight=

  91. J.W. Day, N. Ottaway, J.T. Patterson, V. Gelfanov, D. Smiley, J. Gidda, H. Findeisen, D. Bruemmer, D.J. Drucker, N. Chaudhary, J. Holland, J. Hembree, W. Abplanalp, E. Grant, J. Ruehl, H. Wilson, H. Kirchner, S.H. Lockie, S. Hofmann, S.C. Woods, R. Nogueiras, P.T. Pfluger, D. Perez-Tilve, R. DiMarchi, M.H. Tschöp, A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749–757 (2009)

    Article  PubMed  CAS  Google Scholar 

  92. R.E. Steinert, C. Feinle-Bisset, N. Geary, C. Beglinger, Secretion of gastrointestinal hormones and eating control. J. Anim. Sci. (2013) [Epub ahead of print]

  93. Society for Endocrinology Media Release, Society for Endocrinology website. Hormone combination shows promise in the treatment of obesity and diabetes, http://www.endocrinology.org/press/pressreleases/2013-03-19_GLP1glucagonCombo_SfEBES2013conferencePressRelease.pdf

  94. Y. Xu, T.P. Nedungadi, L. Zhu, N. Sobhani, B.G. Irani, K.E. Davis, X. Zhang, F. Zou, L.M. Gent, L.D. Hahner, S.A. Khan, C.F. Elias, J.K. Elmquist, D.J. Clegg, Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab. 14, 453–465 (2011)

    Article  PubMed  CAS  Google Scholar 

  95. B. Finan, B. Yang, N. Ottaway, K. Stemmer, T.D. Müller, C.X. Yi, K. Habegger, S.C. Schriever, C. García-Cáceres, D.G. Kabra, J. Hembree, J. Holland, C. Raver, R.J. Seeley, W. Hans, M. Irmler, J. Beckers, M.H. de Angelis, J.P. Tiano, F. Mauvais-Jarvis, D. Perez-Tilve, P. Pfluger, L. Zhang, V. Gelfanov, R.D. DiMarchi, M.H. Tschöp, Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847–1856 (2012)

    Article  PubMed  CAS  Google Scholar 

  96. C. Quarta, L. Bellocchio, G. Mancini, R. Mazza, C. Cervino, L.J. Braulke, C. Fekete, R. Latorre, C. Nanni, M. Bucci, L.E. Clemens, G. Heldmaier, M. Watanabe, T. Leste-Lassere, M. Maitre, L. Tedesco, F. Fanelli, S. Reuss, S. Klaus, R.K. Srivastava, K. Monory, A. Valerio, A. Grandis, R. De Giorgio, R. Pasquali, E. Nisoli, D. Cota, B. Lutz, G. Marsicano, U. Pagotto, CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 11, 273–285 (2010)

    Article  PubMed  CAS  Google Scholar 

  97. J. Tam, V.K. Vemuri, J. Liu, S. Bátkai, B. Mukhopadhyay, G. Godlewski, D. Osei-Hyiaman, S. Ohnuma, S.V. Ambudkar, J. Pickel, A. Makriyannis, G. Kunos, Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 120, 2953–2966 (2010)

    Article  PubMed  CAS  Google Scholar 

  98. 7TM Pharma, 7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS, http://7tm.com/News.aspx?M=News&PID=5&NewsID=58. Accessed 17 Nov 2010

  99. S.J. Ward, R.B. Raffa, Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring) 19, 1325–1334 (2011)

    Article  CAS  Google Scholar 

  100. E. Kirilly, X. Gonda, G. Bagdy, CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol. 205, 41–60 (2012)

    CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interests.

Author information

Authors and Affiliations

  1. Endocrinology Unit, Department of Medical and Surgical Sciences, and Center for Applied Biomedical Sciences, S. Orsola—Malpighi Hospital, University Alma Mater Studiorum, Via Massarenti 9, 40138, Bologna, Italy

    Guido Di Dalmazi, Valentina Vicennati, Renato Pasquali & Uberto Pagotto

Authors
  1. Guido Di Dalmazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Vicennati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Renato Pasquali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Uberto Pagotto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uberto Pagotto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Dalmazi, G., Vicennati, V., Pasquali, R. et al. The unrelenting fall of the pharmacological treatment of obesity. Endocrine 44, 598–609 (2013). https://doi.org/10.1007/s12020-013-9983-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-9983-1

Keywords

Search

Navigation